These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23719364)

  • 1. Osteoporosis in men.
    Ebeling PR
    Curr Opin Rheumatol; 2013 Jul; 25(4):542-52. PubMed ID: 23719364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence.
    Sim IeW; Ebeling PR
    Ther Adv Musculoskelet Dis; 2013 Oct; 5(5):259-67. PubMed ID: 24101947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of primary osteoporosis in men.
    Giusti A; Bianchi G
    Clin Interv Aging; 2015; 10():105-15. PubMed ID: 25565793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
    JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
    Zhou J; Ma X; Wang T; Zhai S
    Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.
    Elbers LPB; Raterman HG; Lems WF
    Drugs; 2021 Sep; 81(14):1645-1655. PubMed ID: 34524681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoporosis in men].
    Biver E; Uebelhart B
    Rev Med Suisse; 2013 Jun; 9(390):1260-4. PubMed ID: 23821844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study.
    Wong M; Wan X; Ruff V; Krohn K; Taylor K
    Osteoporos Int; 2012 Apr; 23(4):1445-52. PubMed ID: 21769662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
    Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
    Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy for primary osteoporosis in men].
    Soen S
    Clin Calcium; 2016 Jul; 26(7):1047-52. PubMed ID: 27346317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.